251 related articles for article (PubMed ID: 22512756)
1. Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future.
Lehloenya RJ; Dheda K
Expert Rev Anti Infect Ther; 2012 Apr; 10(4):475-86. PubMed ID: 22512756
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of reintroducing anti-tuberculosis drugs following cutaneous adverse drug reactions.
Lehloenya RJ; Todd G; Badri M; Dheda K
Int J Tuberc Lung Dis; 2011 Dec; 15(12):1649-57. PubMed ID: 22118173
[TBL] [Abstract][Full Text] [Related]
3. CD4 count and risk of anti-tuberculosis drug-associated cutaneous reactions in HIV-infected Thai patients.
Boonyagars L; Hirunwiwatkul P; Hurst CP
Int J Tuberc Lung Dis; 2017 Mar; 21(3):338-344. PubMed ID: 28225346
[TBL] [Abstract][Full Text] [Related]
4. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
5. Multiple drug hypersensitivity reactions to anti-tuberculosis drugs: five cases in HIV-infected patients.
Lehloenya RJ; Wallace J; Todd G; Dheda K
Int J Tuberc Lung Dis; 2012 Sep; 16(9):1260-4. PubMed ID: 22747953
[TBL] [Abstract][Full Text] [Related]
6. Tuberculosis in HIV-infected patients: a comprehensive review.
Aaron L; Saadoun D; Calatroni I; Launay O; Mémain N; Vincent V; Marchal G; Dupont B; Bouchaud O; Valeyre D; Lortholary O
Clin Microbiol Infect; 2004 May; 10(5):388-98. PubMed ID: 15113314
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic patch testing following tuberculosis-associated cutaneous adverse drug reactions induces systemic reactions in HIV-infected persons.
Lehloenya RJ; Todd G; Wallace J; Ngwanya MR; Muloiwa R; Dheda K
Br J Dermatol; 2016 Jul; 175(1):150-6. PubMed ID: 26918554
[TBL] [Abstract][Full Text] [Related]
8. HIV infection-related tuberculosis: clinical manifestations and treatment.
Sterling TR; Pham PA; Chaisson RE
Clin Infect Dis; 2010 May; 50 Suppl 3():S223-30. PubMed ID: 20397952
[TBL] [Abstract][Full Text] [Related]
9. Clinical aspects and treatment outcome in HIV-associated pulmonary tuberculosis: an experience from a Thai referral centre.
Hongthiamthong P; Riantawan P; Subhannachart P; Fuangtong P
J Med Assoc Thai; 1994 Oct; 77(10):520-5. PubMed ID: 7745373
[TBL] [Abstract][Full Text] [Related]
10. HIV-associated tuberculosis: diagnostic and treatment challenges.
El-Sadr WM; Tsiouris SJ
Semin Respir Crit Care Med; 2008 Oct; 29(5):525-31. PubMed ID: 18810685
[TBL] [Abstract][Full Text] [Related]
11. A clinical and epidemiologic update on the interaction between tuberculosis and human immunodeficiency virus infection in adults.
Habib AG
Ann Afr Med; 2009; 8(3):147-55. PubMed ID: 19884690
[TBL] [Abstract][Full Text] [Related]
12. [Tuberculosis and HIV co-infection: a therapeutic challenge].
Charbonnier F; Calmy A; Janssens JP
Rev Med Suisse; 2011 Nov; 7(318):2295-6, 2298-300. PubMed ID: 22400365
[TBL] [Abstract][Full Text] [Related]
13. Anti-HIV agents. Once-daily anti-HIV therapy in people co-infected with TB.
TreatmentUpdate; 2004; 16(3):4-5. PubMed ID: 17219607
[No Abstract] [Full Text] [Related]
14. Bacteriologically confirmed tuberculosis in HIV-infected infants: disease spectrum and survival.
Wiseman CA; Schaaf HS; Cotton MF; Gie RP; Jennings T; Whitelaw A; Roux P; Hesseling AC
Int J Tuberc Lung Dis; 2011 Jun; 15(6):770-5. PubMed ID: 21575297
[TBL] [Abstract][Full Text] [Related]
15. Potential utility of empirical tuberculosis treatment for HIV-infected patients with advanced immunodeficiency in high TB-HIV burden settings.
Lawn SD; Ayles H; Egwaga S; Williams B; Mukadi YD; Santos Filho ED; Godfrey-Faussett P; Granich RM; Harries AD
Int J Tuberc Lung Dis; 2011 Mar; 15(3):287-95. PubMed ID: 21333094
[TBL] [Abstract][Full Text] [Related]
16. Optimum time to start antiretroviral therapy in patients with HIV-associated tuberculosis: before or after tuberculosis diagnosis?
Kerkhoff AD; Wood R; Lawn SD
AIDS; 2011 Apr; 25(7):1003-6. PubMed ID: 21346513
[TBL] [Abstract][Full Text] [Related]
17. Funding. Experts look for more to fight TB, HIV/AIDS coinfection.
AIDS Policy Law; 2009 Sep; 24(10):3. PubMed ID: 19827208
[No Abstract] [Full Text] [Related]
18. HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone free anti-tuberculosis treatment in Yaounde, Cameroon.
Kuaban C; Bercion R; Koulla-Shiro S
East Afr Med J; 1997 Aug; 74(8):474-7. PubMed ID: 9487410
[TBL] [Abstract][Full Text] [Related]
19. Pediatric tuberculosis: global overview and challenges.
Swaminathan S; Rekha B
Clin Infect Dis; 2010 May; 50 Suppl 3():S184-94. PubMed ID: 20397947
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of cutaneous drug eruptions in adult Nigerians with HIV/AIDS.
Salami TA; Asalu AF; Samuel SO
Niger Postgrad Med J; 2010 Jun; 17(2):160-3. PubMed ID: 20539333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
